OBJECTIVE: To assess adherence to community-based directly observed treatment (DOT) among Tanzanian tuberculosis patients using the Medication Event Monitoring System (MEMS) and to validate alternative adherence measures for resource-limited settings using MEMS as a gold standard. METHODS: This was a longitudinal pilot study of 50 patients recruited consecutively from one rural hospital, one urban hospital and two urban health centres. Treatment adherence was monitored with MEMS and the validity of the following adherence measures was assessed: isoniazid urine test, urine colour test, Morisky scale, Brief Medication Questionnaire, adapted AIDS Clinical Trials Group (ACTG) adherence questionnaire, pill counts and medication refill visits. FINDINGS: The mean adherence rate in the study population was 96.3% (standard deviation, SD: 7.7). Adherence was less than 100% in 70% of the patients, less than 95% in 21% of them, and less than 80% in 2%. The ACTG adherence questionnaire and urine colour test had the highest sensitivities but lowest specificities. The Morisky scale and refill visits had the highest specificities but lowest sensitivities. Pill counts and refill visits combined, used in routine practice, yielded moderate sensitivity and specificity, but sensitivity improved when the ACTG adherence questionnaire was added. CONCLUSION: Patients on community-based DOT showed good adherence in this study. The combination of pill counts, refill visits and the ACTG adherence questionnaire could be used to monitor adherence in settings where MEMS is not affordable. The findings with regard to adherence and to the validity of simple adherence measures should be confirmed in larger populations with wider variability in adherence rates.
OBJECTIVE: To assess adherence to community-based directly observed treatment (DOT) among Tanzanian tuberculosispatients using the Medication Event Monitoring System (MEMS) and to validate alternative adherence measures for resource-limited settings using MEMS as a gold standard. METHODS: This was a longitudinal pilot study of 50 patients recruited consecutively from one rural hospital, one urban hospital and two urban health centres. Treatment adherence was monitored with MEMS and the validity of the following adherence measures was assessed: isoniazid urine test, urine colour test, Morisky scale, Brief Medication Questionnaire, adapted AIDS Clinical Trials Group (ACTG) adherence questionnaire, pill counts and medication refill visits. FINDINGS: The mean adherence rate in the study population was 96.3% (standard deviation, SD: 7.7). Adherence was less than 100% in 70% of the patients, less than 95% in 21% of them, and less than 80% in 2%. The ACTG adherence questionnaire and urine colour test had the highest sensitivities but lowest specificities. The Morisky scale and refill visits had the highest specificities but lowest sensitivities. Pill counts and refill visits combined, used in routine practice, yielded moderate sensitivity and specificity, but sensitivity improved when the ACTG adherence questionnaire was added. CONCLUSION:Patients on community-based DOT showed good adherence in this study. The combination of pill counts, refill visits and the ACTG adherence questionnaire could be used to monitor adherence in settings where MEMS is not affordable. The findings with regard to adherence and to the validity of simple adherence measures should be confirmed in larger populations with wider variability in adherence rates.
Authors: J H Arnsten; P A Demas; H Farzadegan; R W Grant; M N Gourevitch; C J Chang; D Buono; H Eckholdt; A A Howard; E E Schoenbaum Journal: Clin Infect Dis Date: 2001-09-05 Impact factor: 9.079
Authors: Cynthia L Russell; Sarah Owens; Karen Q Hamburger; Denise A Thompson; Rebecca R Leach; Muammer Cetingok; Donna Hathaway; Vicki S Conn; Catherine Ashbaugh; Leanne Peace; Richard Madsen; Rebecca P Winsett; Mark R Wakefield Journal: J Gerontol Nurs Date: 2009-10-09 Impact factor: 1.254
Authors: J van den Boogaard; R Lyimo; C F Irongo; M J Boeree; H Schaalma; R E Aarnoutse; G S Kibiki Journal: Int J Tuberc Lung Dis Date: 2009-12 Impact factor: 2.373
Authors: R Ruslami; R van Crevel; E van de Berge; B Alisjahbana; R E Aarnoutse Journal: Southeast Asian J Trop Med Public Health Date: 2008-11 Impact factor: 0.267
Authors: Kris Denhaerynck; Petra Schäfer-Keller; James Young; Jürg Steiger; Andreas Bock; Sabina De Geest Journal: BMC Med Res Methodol Date: 2008-02-19 Impact factor: 4.615
Authors: James H McMahon; Anand Manoharan; Christine A Wanke; Shoba Mammen; Hepsibah Jose; Thabeetha Malini; Tony Kadavanu; Michael R Jordan; Julian H Elliott; Sharon R Lewin; Dilip Mathai Journal: AIDS Behav Date: 2013-07
Authors: Abdallah Mkopi; Nyagosya Range; Fred Lwilla; Saidi Egwaga; Alexander Schulze; Eveline Geubbels; Frank van Leth Journal: PLoS One Date: 2012-12-19 Impact factor: 3.240
Authors: Elizabeth J Ragan; Christopher J Gill; Matthew Banos; Tara C Bouton; Jennifer Rooney; Charles R Horsburgh; Robin M Warren; Bronwyn Myers; Karen R Jacobson Journal: JMIR Res Protoc Date: 2021-06-16